A considerable number of individuals who passed away subsequent to receiving the Moderna vaccine did not undergo autopsy procedures. As per a study, 16 individuals died after being vaccinated with Moderna’s vaccine. The authors of the study reported that among these 16 deaths, only two individuals underwent autopsies, five were not subjected to autopsies, and the autopsy status of the remaining nine was ‘uncertain’.
As a result of Defending the Republic’s (DTR) successful Freedom of Information Act (FOIA) litigation against the Food and Drug Administration (FDA), we are excited to announce that we are releasing nearly 15,000 pages of documents relating to testing and adverse events associated with Moderna’s COVID-19 vaccine ‘Spikevax.’Defending the Republic [DTR]
DTR initiated a FOIA lawsuit against the FDA when the request for an expedited release of Moderna COVID-19 records was denied. The FDA stated that there was no urgent necessity for the public to access this information. In the spring, DTR and the FDA reached an agreement to obtain approximately 24,000 pages of crucial records submitted by Moderna in support of its Biologics License Application (BLA). This is the initial portion of the documents to be produced, with approximately 8,000 more pages scheduled for release later this year.
These documents are significant as they represent the first substantial data release from Moderna’s COVID-19 clinical trials. They contain information on the causes of deaths, serious adverse events, and potential instances of neurological disorders (such as Bell’s Palsy and Shingles) linked to Moderna’s COVID-19 vaccine.
Of particular note, these records also reveal the inadequate rigor of these studies. Notably, a number of individuals who died after receiving the Moderna vaccine did not undergo autopsy procedures. According to a study, 16 individuals died following administration of the Moderna vaccine, but only two of these deaths were subjected to autopsies. Five of the deceased were not autopsied, and the autopsy status of nine individuals remains ‘unknown’.
Despite the lack of evidence, those conducting these ‘studies’ concluded that the Moderna vaccine was not linked to the reported deaths. For instance, a 56-year-old woman experienced ‘sudden death’ 182 days after her second Moderna vaccine dose, but no investigation or autopsy was conducted to determine the cause of death. It appears that they deliberately chose not to investigate suspicious deaths that could potentially be attributed to the Moderna vaccine.
The studies also revealed numerous instances of post-vaccination Bell’s Palsy and Shingles (Herpes Zoster) among participants. For example, a 44-year-old woman suffered from ‘left side facial paralysis’ just eight days after receiving the second dose, and several vaccinated individuals developed Shingles within 10 days of vaccination.
Additionally, the vaccinated groups experienced serious adverse events, such as myocardial infarction (heart attack), pulmonary embolism, spontaneous abortion/miscarriage, transient ischemic attack (TIA), and lymphoma. Subsequent analyses of reports from various databases showed increased rates of these illnesses following administration of the Moderna vaccine. Yet, similar to their handling of post-vaccination deaths, the studies seemed predisposed to conclude that these serious adverse events, many of which were life-threatening, were not connected to the Moderna vaccine, regardless of the close temporal association with vaccination. This raises serious concerns about the safety of the Moderna vaccine and the FDA’s standards and approval process.
As part of the FDA’s production, DTR received the results of a study titled ‘A GLP Intramuscular Combined Developmental and Perinatal/Postnatal Reproductive Toxicity Study of mRNA-1273 in Rats.’ The study aimed to assess the potential effects of mRNA-1273, a vaccine candidate against SARS-CoV-2 infection, on fertility and pre and postnatal development in pregnant and lactating female Sprague Dawley CD (Crl:CD[SD]) rats. The findings of this study are troubling, as the mRNA vaccine led to skeletal variations in rat fetuses, and the ‘female pregnancy index’ of vaccinated rats was significantly lower than that of the control group. DTR, through its FOIA lawsuit, is providing the full study, although a summary of it was previously reported.
Here are the main findings and observations from the study:
- Some skeletal variations related to mRNA-1273 were noted, including wavy ribs and increased nodules. Wavy ribs were observed in 6 fetuses from 4 litters, with a fetal prevalence of 4.03% and a litter prevalence of 18.2%. Rib nodules were present in 5 out of those 6 fetuses. The incidence of wavy ribs in fetuses and litters surpassed the historical range observed at the Testing Facility (see Appendix 40, Historical Control Data), while the incidence of rib nodules fell within the historical range.
- The non-adverse effects attributed to mRNA-1273 were limited to an increase in the number of fetuses with common skeletal variations, such as one or more rib nodules and one or more wavy ribs.
- The mean number of reproductive cycle lengths was statistically significantly higher in the mRNA-1273 group compared to the control group.
- Mating occurred in 95.5% of the rats in the control group and 88.6% of the rats in the mRNA-1273 group.
- The female pregnancy index (number of rats mating/number of rats in the group) was 93.2% for the control group and 84.1% for the mRNA-1273 group.
- During scheduled euthanasia, two pups from the mRNA-1273 dose group were observed with minor renal papilla abnormalities (one with bilateral, small, minimal renal papilla and the other with left, small, moderate renal papilla). These findings were not considered to be related to mRNA-1273 because they were observed in only two pups from the same litter.
Finally, as part of the FOIA production, a Moderna study from 2017-2018 was included. This study, titled ‘A Single Dose Intramuscular Injection Tissue Distribution Study of mRNA-1647 in Male Sprague-Dawley Rats,’ was submitted as part of the Spikevax Biologics License Application (BLA). It’s important to note that the mRNA-1647 vaccine was developed before Moderna’s COVID-19 vaccine.
The main objectives of this study were twofold: first, to determine the tissue distribution of mRNA-1647 after a single intramuscular injection in rats, and second, to assess the toxicokinetic characteristics of mRNA-1647.
The testing results showed that mRNA-1647 was present in all of the analyzed tissues, except for the kidney. Elevated levels of mRNA-1647 were particularly found in the spleen and eye. Notably, the study also detected mRNA-1647 in the brain and heart, as indicated in the charts below.